Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium

Rhea-AI Summary

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, will host a live webcast and conference call on October 28, 2022, at 8:30 a.m. EDT, to discuss preliminary Phase 1 data from the ARROS-1 clinical trial of NVL-520, alongside additional preclinical updates. This event coincides with the 34th EORTC-NCI-AACR Symposium in Barcelona, Spain. Interested parties can access the webcast via Nuvalent’s investor page or by phone using the provided dial-in details.

Positive

• Nuvalent is advancing a pipeline targeting ROS1-positive and ALK-positive non-small cell lung cancer.
• The company is also focusing on HER2 Exon 20 insertion-positive cancers.

Negative

• None.

CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that management will host a live webcast and conference call in conjunction with its data presentations at the 34th EORTC-NCI-AACR (ENA) Symposium in Barcelona, Spain on Friday, October 28, 2022 at 8:30 a.m. EDT.

The event will be accessible through the "Events" section of the Investors page of www.nuvalent.com or by dialing (866) 652-5200 (domestic) or (412) 317-6060 (international) and referring to conference ID 10171503. A replay and accompanying slides will be archived on the Nuvalent website for 30 days.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), a program in HER2 Exon 20 insertion-positive cancers, along with multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter (@nuvalent) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-host-conference-call-to-discuss-preliminary-phase-1-data-from-arros-1-clinical-trial-of-nvl-520-and-additional-preclinical-updates-in-conjunction-with-34th-eortc-nci-aacr-symposium-301650281.html

SOURCE Nuvalent, Inc.

FAQ

What data will Nuvalent present at the EORTC-NCI-AACR Symposium on October 28, 2022?

Nuvalent will present preliminary Phase 1 data from its ARROS-1 clinical trial of NVL-520.

How can I access the Nuvalent conference call?

The conference call can be accessed through the 'Events' section on Nuvalent's investor page or via phone using the provided numbers.

What is the focus of Nuvalent's research and development?

Nuvalent focuses on developing targeted therapies for cancer, specifically for ROS1-positive and ALK-positive non-small cell lung cancer, and HER2 Exon 20 insertion-positive cancers.